Home LiteratureArticle Details
PMID: 1764870 Published · ppublish English Journal Article Review

Omeprazole drug interaction studies.

Clinical pharmacokinetics ·Vol. 21 ·No. 3 ·1991-09-00 ·Pages 195-212

Andersson T

Abstract

This review examines the literature on drug interactions with omeprazole. Different mechanisms have been proposed as potential causes for such interactions. First, the absorption of some drugs might be altered due to the decreased intragastric acidity resulting from omeprazole treatment. There was no effect of omeprazole on the absorption of amoxycillin, bacampicillin and alcohol, while the amount of digoxin and nifedipine absorbed was increased by 10 and 21%, respectively, both increases probably being of no clinical significance. Secondly, the metabolism of high clearance drugs might be altered by changes in liver blood flow, although that is not affected by omeprazole, as indicated by the unchanged elimination of indocyanine green. In addition, the clearance of intravenously administered lidocaine (lignocaine) [a high clearance drug] was unaffected by omeprazole, further indicating that the latter does not alter liver blood flow. Thirdly, since omeprazole is a substituted benzimidazole, it might have the potential to interfere with the metabolism of other drugs by altering the activity of drug metabolising enzymes in the cytochrome P450 system, through either induction or inhibition. There is no indication of induction of this enzyme system in any interaction study with omeprazole. As regards inhibition, on the other hand, there is now considerable information available which indicates that omeprazole has the potential to partly inhibit the metabolism of drugs metabolised to a great extent by the cytochrome P450 enzyme subfamily IIC (diazepam, phenytoin), but not of those metabolised by subfamilies IA (caffeine, theophylline), IID (metoprolol, propranolol) and IIIA (cyclosporin, lidocaine, quinidine). Since relatively few drugs are metabolised mainly by IIC compared with IID and IIIA, the potential for omeprazole to interfere with the metabolism of other drugs appears to be limited.

MeSH Terms
Absorption/drug effects Biomarkers/chemistry Cytochrome P-450 Enzyme System/metabolism Drug Interactions Humans Liver Circulation/drug effects Omeprazole/pharmacology Pharmaceutical Preparations/metabolism
Chemicals
Biomarkers Pharmaceutical Preparations Cytochrome P-450 Enzyme System Omeprazole
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Andersson T
Department of Clinical Pharmacology, Hässle Research Laboratories, Mölndal, Sweden.
References (83)
83 references, click to expand
  1. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
    J Cardiovasc Pharmacol. 1990 May;15(5):776-9 PMID: 1692938
  2. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem.
    Drug Metab Dispos. 1990 Sep-Oct;18(5):711-9 PMID: 1981725
  3. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
    Mol Pharmacol. 1989 Jul;36(1):89-96 PMID: 2787473
  4. The antipyrine test in clinical pharmacology: conceptions and misconceptions.
    Clin Pharmacol Ther. 1979 Sep;26(3):275-86 PMID: 111889
  5. A urinary metabolite ratio that reflects systemic caffeine clearance.
    Clin Pharmacol Ther. 1987 Aug;42(2):157-65 PMID: 3608349
  6. Ethanol metabolism and ethanol-drug interactions.
    Biochem Pharmacol. 1976 Apr 15;25(8):869-75 PMID: 773384
  7. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.
    Br J Clin Pharmacol. 1989 Oct;28(4):373-87 PMID: 2590599
  8. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.
    Lancet. 1987 Feb 14;1(8529):349-51 PMID: 2880161
  9. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.
    Br J Clin Pharmacol. 1990 Jun;29(6):651-63 PMID: 2378786
  10. Does gastric aminopyrine clearance reflect gastric mucosal blood flow or parietal cell function?
    Gut. 1981 Dec;22(12):997-1002 PMID: 7319289
  11. Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies.
    Biochem Pharmacol. 1987 Apr 15;36(8):1251-60 PMID: 3593412
  12. Biliary excretion of intravenous [14C] omeprazole in humans.
    Clin Pharmacol Ther. 1987 Nov;42(5):504-8 PMID: 3677539
  13. Omeprazole treatment does not affect the metabolism of caffeine.
    Gastroenterology. 1991 Oct;101(4):943-7 PMID: 1889718
  14. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
    J Biol Chem. 1989 Jun 25;264(18):10388-95 PMID: 2732228
  15. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Scand J Gastroenterol. 1984 Oct;19(7):916-22 PMID: 6531660
  16. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.
    Gastroenterology. 1990 Sep;99(3):737-47 PMID: 2136526
  17. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci.
    DNA. 1989 Jan-Feb;8(1):1-13 PMID: 2651058
  18. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.
    Ther Drug Monit. 1990 Jul;12(4):415-6 PMID: 2396316
  19. Identification of an inducible form of cytochrome P-450 in human liver.
    Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310-4 PMID: 3898085
  20. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Clin Pharmacol Ther. 1989 Apr;45(4):348-55 PMID: 2495208
  21. Ranitidine drug interactions--a literature review.
    Pharmacol Ther. 1987;32(3):293-325 PMID: 3310029
  22. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.
    Biochem Pharmacol. 1988 May 1;37(9):1651-9 PMID: 3288213
  23. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    J Pharmacol Exp Ther. 1989 Apr;249(1):134-42 PMID: 2496225
  24. Evolution of cytochrome P-450 proteins.
    Mol Biol Evol. 1987 Nov;4(6):572-93 PMID: 3484338
  25. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.
    Eur J Clin Pharmacol. 1991;40(1):61-5 PMID: 2060547
  26. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.
    Clin Pharmacol Ther. 1990 Jan;47(1):79-85 PMID: 2104790
  27. Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
    Gastroenterology. 1988 Oct;95(4):903-12 PMID: 3044912
  28. Oral phenytoin pharmacokinetics during omeprazole therapy.
    Br J Clin Pharmacol. 1987 Oct;24(4):543-5 PMID: 3689634
  29. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.
    Clin Pharmacol Ther. 1986 Sep;40(3):344-51 PMID: 3742939
  30. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.
    DNA. 1988 Mar;7(2):79-86 PMID: 3267210
  31. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
    J Pharmacol Exp Ther. 1988 Jun;245(3):845-9 PMID: 3385644
  32. The polymorphic oxidation of beta-adrenoceptor antagonists.
    Pharmacol Ther. 1989;41(3):461-77 PMID: 2566179
  33. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Clin Pharmacol Ther. 1989 Jan;45(1):72-9 PMID: 2910639
  34. Omeprazole: effects on oxidative drug metabolism.
    Br J Clin Pharmacol. 1984 Aug;18(2):195-200 PMID: 6487457
  35. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Eur J Clin Pharmacol. 1984;26(6):753-9 PMID: 6489416
  36. A study of the interaction between omeprazole and phenytoin in epileptic patients.
    Ther Drug Monit. 1990 Jul;12(4):329-33 PMID: 2396305
  37. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Pharmacol Ther. 1990;46(3):377-94 PMID: 2188269
  38. Enzyme induction and inhibition.
    Pharmacol Ther. 1990;48(1):71-94 PMID: 2274578
  39. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo.
    Pharmacol Ther. 1987;33(1):133-7 PMID: 2888140
  40. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.
    Gut. 1983 Apr;24(4):270-6 PMID: 6832622
  41. Drug interaction between propafenone and metoprolol.
    Br J Clin Pharmacol. 1987 Aug;24(2):213-20 PMID: 3620296
  42. Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists.
    Int J Immunopharmacol. 1984;6(5):467-73 PMID: 6150013
  43. Pharmacokinetic drug interactions with cyclosporin (Part II).
    Clin Pharmacokinet. 1990 Nov;19(5):400-15 PMID: 2268987
  44. Polymorphism of cytochrome P-450 in humans.
    Trends Pharmacol Sci. 1989 Mar;10(3):107-9 PMID: 2688217
  45. The molecular biology of cytochrome P450s.
    Pharmacol Rev. 1988 Dec;40(4):243-88 PMID: 3072575
  46. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.
    Clin Pharmacol Ther. 1989 Nov;46(5):521-7 PMID: 2582709
  47. Propranolol steady-state pharmacokinetics are unaltered by omeprazole.
    Eur J Clin Pharmacol. 1987;33(4):369-73 PMID: 3443142
  48. Oxidation of quinidine by human liver cytochrome P-450.
    Mol Pharmacol. 1986 Sep;30(3):287-95 PMID: 3748010
  49. The mechanism of action of the gastric acid secretion inhibitor omeprazole.
    J Med Chem. 1986 Aug;29(8):1327-9 PMID: 3016260
  50. Hepatic drug clearance: the effect of age using indocyanine green as a model compound.
    Br J Clin Pharmacol. 1990 Oct;30(4):634-7 PMID: 2291878
  51. Polymorphic hydroxylation of Debrisoquine in man.
    Lancet. 1977 Sep 17;2(8038):584-6 PMID: 71400
  52. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers.
    J Clin Gastroenterol. 1986 Aug;8(4):408-13 PMID: 3531313
  53. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer.
    N Engl J Med. 1989 Jan 12;320(2):69-75 PMID: 2643037
  54. The relationship between the binding of 2-n-alkylbenzimidazoles to rat hepatic microsomal cytochrome P-450 and the inhibition of monooxygenation.
    Biochem Pharmacol. 1982 Apr 1;31(7):1315-20 PMID: 7092924
  55. Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase.
    Biochemistry. 1986 Nov 4;25(22):6731-5 PMID: 3801389
  56. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
    Mol Pharmacol. 1990 Aug;38(2):207-13 PMID: 2385232
  57. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.
    Br J Clin Pharmacol. 1988 Oct;26(4):363-72 PMID: 3190986
  58. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450.
    Mol Pharmacol. 1988 May;33(5):500-8 PMID: 3285175
  59. Genetic polymorphism of S-mephenytoin hydroxylation.
    Pharmacol Ther. 1989;43(1):53-76 PMID: 2675129
  60. Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.
    Clin Pharmacokinet. 1988 Jul;15(1):44-56 PMID: 3042245
  61. Pharmacokinetic drug interactions with cyclosporin (Part I).
    Clin Pharmacokinet. 1990 Oct;19(4):319-32 PMID: 2208899
  62. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2.
    Arch Biochem Biophys. 1989 Jun;271(2):270-83 PMID: 2729995
  63. Stereoselective interaction of omeprazole with warfarin in healthy men.
    Ther Drug Monit. 1989;11(2):176-84 PMID: 2718223
  64. Effect of omeprazole and cimetidine on plasma diazepam levels.
    Eur J Clin Pharmacol. 1990;39(1):51-4 PMID: 2276389
  65. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
    Gut. 1984 Sep;25(9):957-64 PMID: 6469081
  66. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.
    Nature. 1981 Mar 12;290(5802):159-61 PMID: 6259537
  67. Histamine H1- and H2-receptors in the gastrointestinal circulation.
    Naunyn Schmiedebergs Arch Pharmacol. 1980 Jun;312(2):123-9 PMID: 6105622
  68. Omeprazole: pharmacokinetics and metabolism in man.
    Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2 PMID: 2690330
  69. Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis.
    Clin Pharmacol Ther. 1980 Jan;27(1):16-21 PMID: 7351113
  70. Bioavailability studies on a buffered acetylsalicylic acid preparation.
    Acta Pharm Suec. 1975;12(4):323-32 PMID: 1106118
  71. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
    Clin Pharmacol Ther. 1985 Oct;38(4):414-8 PMID: 4042524
  72. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
    J Pharmacol Exp Ther. 1990 Jan;252(1):442-7 PMID: 2299601
  73. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.
    Biochemistry. 1987 Dec 15;26(25):8466-74 PMID: 3442670
  74. Histamine H1- and H2-receptor vasodilation of canine intestinal circulation.
    Am J Physiol. 1977 Sep;233(3):E219-24 PMID: 910911
  75. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.
    Clin Pharmacol Ther. 1988 Jun;43(6):630-5 PMID: 3378384
  76. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin.
    Scand J Infect Dis. 1989;21(2):219-23 PMID: 2727638
  77. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Eur J Clin Pharmacol. 1989;36(6):537-47 PMID: 2570698
  78. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.
    Gastroenterology. 1985 Dec;89(6):1235-41 PMID: 3932118
  79. Distribution of cytochromes P-450, cytochrome b5, and NADPH-cytochrome P-450 reductase in an entire human liver.
    Biochem Pharmacol. 1990 Feb 1;39(3):471-6 PMID: 2106322
  80. Omeprazole: pharmacology, pharmacokinetics and interactions.
    Digestion. 1989;44 Suppl 1:9-17 PMID: 2691315
  81. A role for histamine type II (H-2) receptor binding in production of the lymphokine, soluble immune response suppressor (SIRS).
    J Immunol. 1987 Aug 15;139(4):1185-90 PMID: 2440946
  82. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Clin Pharmacol Ther. 1987 Sep;42(3):278-82 PMID: 3621781
  83. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
    Ther Drug Monit. 1990 Mar;12 (2):163-72 PMID: 2315973
Article Info
Journal
Clinical pharmacokinetics
Abbr.
Clin Pharmacokinet
ISSN
0312-5963
DOI
10.2165/00003088-199121030-00004
Published
1991-09-00
Pages
195-212
Language
English
Region
Switzerland
NLM ID
7606849
Subset
IM
External Links
PubMed source DOI: 10.2165/00003088-199121030-00004 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2